Current Report Filing (8-k)
October 31 2019 - 7:37AM
Edgar (US Regulatory)
0000816284
false
0000816284
2019-10-30
2019-10-31
0000816284
us-gaap:CommonStockMember
2019-10-30
2019-10-31
0000816284
celg:ContingentValueRightsMember
2019-10-30
2019-10-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): October 31, 2019
CELGENE CORPORATION
(Exact Name of Registrant as Specified in
Charter)
|
Delaware
|
|
001-34912
|
|
22-2711928
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
86 Morris Avenue
Summit, NJ 07901
(Address of Principal Executive Offices,
and Zip Code)
(908)
673-9000
Registrant’s Telephone Number, Including Area Code
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
|
¨
|
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, par value $.01 per share
|
|
CELG
|
|
NASDAQ Global Select Market
|
|
Contingent Value Rights
|
|
CELGZ
|
|
NASDAQ Global Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
ITEM
2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On October 31, 2019, Celgene Corporation
issued a press release announcing its financial results for its fiscal quarter ended September 30, 2019. A copy of this press release
is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
In accordance with General Instruction B.2
of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, that is furnished pursuant to this Item
2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated
by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange
Act, except as shall be expressly set forth by specific reference in such filing.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
|
(d) Exhibit 99.1
|
Press Release dated October 31, 2019 announcing results for the quarter ended September 30, 2019.
|
This exhibit is furnished pursuant to Item
2.02 and shall not be deemed to be “filed.”
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
CELGENE CORPORATION
|
|
|
|
|
|
Date: October 31, 2019
|
By:
|
/s/ David V. Elkins
|
|
|
|
David V. Elkins
|
|
|
|
Executive Vice President
|
|
|
|
Chief Financial Officer
|
|
|
|
(principal financial and accounting officer)
|
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024
